SpringWorks Therapeutics, Inc. (SWTX)
NASDAQ: SWTX · Real-Time Price · USD
46.97
+0.01 (0.02%)
At close: Jun 25, 2025, 4:00 PM
46.97
0.00 (0.00%)
Pre-market: Jun 26, 2025, 7:08 AM EDT
SpringWorks Therapeutics Revenue
SpringWorks Therapeutics had revenue of $49.09M in the quarter ending March 31, 2025, with 133.68% growth. This brings the company's revenue in the last twelve months to $219.67M, up 730.42% year-over-year. In the year 2024, SpringWorks Therapeutics had annual revenue of $191.59M with 3,417.33% growth.
Revenue (ttm)
$219.67M
Revenue Growth
+730.42%
P/S Ratio
15.91
Revenue / Employee
$596,929
Employees
368
Market Cap
3.54B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SWTX News
- 6 days ago - SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors - GlobeNewsWire
- 22 days ago - SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX - Business Wire
- 4 weeks ago - SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN - GlobeNewsWire
- 2 months ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc. - PRNewsWire
- 2 months ago - Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B - Investopedia
- 2 months ago - Germany's Merck Set to Buy SpringWorks in $3.9 Billion Deal - WSJ
- 2 months ago - Germany's Merck KGaA in $3.9 bln deal to acquire US biotech firm SpringWorks - Reuters
- 2 months ago - Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business - GlobeNewsWire